02/17/2026
We have received an uptick in questions related to this substance. We felt it was best to share our policy here to bring attention to it.
OCB adheres to WADA guidelines for doping control. WADA added BPC-157 to the S0 “Non-Approved Substances” category in its Prohibited List (effective 2022). This group includes any pharmacological compound that has not been approved for human therapeutic use by any regulatory health authority (e.g., FDA, EMA). BPC-157 hasn’t passed the rigorous clinical testing required to be licensed as a drug anywhere, so it falls into this catch-all banned category.
If WADA ever changes their policy on this substance, OCB will follow in kind.
WADA bans substances when they meet one or more of these criteria—and BPC-157 checks multiple boxes:
Potential performance enhancement:
•It appears to speed up injury recovery, tissue repair, and healing.
•Faster recovery = competitive advantage, even if it’s not a classic “muscle-builder”
Not an approved medication:
•It’s not FDA-approved (or approved by equivalent regulators)
•No standardized dosing, purity, or manufacturing controls
•Insufficient human safety data. Most evidence comes from rats, not people
•Unknown risks with long-term use (cancer signaling, abnormal tissue growth, hormonal effects are all theoretical concerns)
Often sold in a gray/black market
•Frequently labeled “research chemical”
•Quality, contamination, and dosing can be wildly inconsistent
🔗https://ocbonline.com/drug-testing/
